Treatment Authorization Request For Buprenorphine and Suboxone No Longer Required By Medi-Cal

By John Lavitt 08/28/15

Medi-Cal patients in need of Suboxone will still need a DEA waiver.

Image: 
doctorpatientpronews.png
Shutterstock

According to the California Society of Addiction Medicine, Medi-Cal has decided to help patients with opioid substance abuse disorder get buprenorphine products like Suboxone.

A Treatment Authorization Request (TAR) for most buprenorphine products like Suboxone is no longer required by Medi-Cal, providing greater time management options for both Medi-Cal recipients and their doctors. This reform will make it much easier for patients to get Suboxone prescriptions filled in a timely manner. 

Both a Drug Enforcement Administration waiver and a diagnosis of opioid addiction are still required, but these can be quickly obtained when the drug is prescribed. There remains a maximum of 120 units and a 30-day supply of the drugs.

A TAR for Medi-Cal patients is necessary to receive certain kinds of healthcare services from medical, pharmacy, or dental providers enrolled in the program. Providers must receive authorization from Medi-Cal in order to provide and/or be paid for some of these services.

As the California Department of Healthcare Services explains, “TARs are used by Medi-Cal to help ensure that necessary medical, pharmacy, or dental services are provided to Medi-Cal recipients and that providers are reimbursed appropriately.” When it came to buprenorphine products like Suboxone, the issue was less about reimbursement and more of an example of the ongoing resistance to medication-assisted treatment for opioid substance abuse disorder.

The problem with TAR was the delays that go hand-in-hand with government bureaucracy and the stopgap in treatment as a result of such delays. When a Medi-Cal recipient is willing to take the step to access treatment for the disease of addiction, such willingness needs to be responded to quickly with a doctor’s ability to judge trusted by the state. The removal of the requirement of TARs for the prescribing of buprenorphine products like Suboxone is a step in the right direction.

Please read our comment policy. - The Fix
Disqus comments
John_Lavitt_Pic.jpg

Growing up in Manhattan as a stutterer, John Lavitt discovered that writing was the best way to express himself when the words would not come. After graduating with honors from Brown University, he lived on the Greek island of Patmos, studying with his mentor, the late American poet Robert Lax. As a writer, John’s published work includes three articles in Chicken Soup For The Soul volumes and poems in multiple poetry journals and compilations. Active in recovery, John has been the Treatment Professional News Editor for The Fix. Since 2015, he has published over 500 articles on the addiction and recovery news website. Today, he lives in Los Angeles with his beautiful wife, trying his best to be happy and creative. Find John on Facebook, Twitter, and LinkedIn.

Disqus comments